C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2026)
C4 Therapeutics' quarterly Capital Expenditures came in at $38000.0 in Q1 2026, up 245.45% quarter-over-quarter from $11000.0 in Q4 2025.
C4 Therapeutics has reported Capital Expenditures for 8 years, with the latest figure at $38000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $38000.0; the trailing twelve-month figure through Mar 2026 stood at $645000.0 (up 258.33% YoY), and the FY2025 full-year result was $607000.0, up 237.22% from the prior year.
- Capital Expenditures for Q1 2026 stood at $38000.0, up from $11000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $3.1 million in Q2 2022, with the low at -$1.8 million in Q3 2022.
- Average Capital Expenditures over 5 years is $87733.3, with a median of $38000.0 recorded in 2026.
- Year-over-year, Capital Expenditures sank 1000.92% in 2022 and soared 2161.54% in 2025.
- Tracing CCCC's Capital Expenditures over 5 years: stood at -$982000.0 in 2022, then slumped by 56.11% to -$1.5 million in 2023, then jumped by 99.74% to -$4000.0 in 2024, then jumped by 375.0% to $11000.0 in 2025, then soared by 245.45% to $38000.0 in 2026.
- The last three Capital Expenditures figures came in at $38000.0 (Q1 2026), $11000.0 (Q4 2025), and $302000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | 38,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38,000.00 |
| Mar 31, 2026 | 38,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Dec 31, 2025 | 11,000.00 |
| Sep 30, 2025 | 302,000.00 |
| Sep 30, 2025 | 302,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Dec 31, 2024 | -4,000.00 |
| Dec 31, 2024 | -4,000.00 |
| Sep 30, 2024 | 171,000.00 |
| Sep 30, 2024 | 171,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Dec 31, 2023 | -1.53 Mn |
| Dec 31, 2023 | -1.53 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 27,000.00 |
| Jun 30, 2023 | 27,000.00 |
| Mar 31, 2023 | 196,000.00 |
| Mar 31, 2023 | 196,000.00 |
| Dec 31, 2022 | -982,000.00 |
| Dec 31, 2022 | -982,000.00 |
| Sep 30, 2022 | -1.82 Mn |
| Sep 30, 2022 | -1.82 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 172,000.00 |
| Mar 31, 2022 | 172,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Jun 30, 2021 | 747,000.00 |
| Jun 30, 2021 | 747,000.00 |
| Mar 31, 2021 | 421,000.00 |
| Mar 31, 2021 | 421,000.00 |
| Dec 31, 2020 | 640,000.00 |
| Dec 31, 2020 | 640,000.00 |
| Sep 30, 2020 | -65,000.00 |
| Sep 30, 2020 | -65,000.00 |
| Jun 30, 2020 | 63,000.00 |
| Jun 30, 2020 | 63,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Dec 31, 2019 | 1.25 Mn |
| Dec 31, 2019 | 1.25 Mn |